Par Drugs & Chemical Intrinsic Value
Par Drugs & Chemical (PAR) median intrinsic value is ₹149.55 from 9 valuation models (range ₹78–₹234), vs current price ₹91.00 — +64.3% upside (Trading Below Calculated Value), margin of safety 39.2%. Browse Par Drugs & Chemical financial data for revenue, profit, balance sheet and cash flow data.
PAR Valuation Methods Summary — DCF, Graham Number & P/E
Par Drugs & Chemical intrinsic value across 9 models vs current price ₹91.00 — upside/downside and value range per method. For current market price and key ratios, visit Par Drugs & Chemical share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹234.30 | ₹187.44 - ₹281.16 | +157.5% | EPS: ₹10.65, Sector P/E: 22x |
| Book Value Method | asset | ₹186.67 | ₹168.00 - ₹205.34 | +105.1% | Book Value/Share: ₹93.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹173.33 | ₹156.00 - ₹190.66 | +90.5% | Revenue/Share: ₹86.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹141.67 | ₹127.50 - ₹155.84 | +55.7% | EBITDA: ₹17.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹136.16 | ₹108.93 - ₹163.39 | +49.6% | CF Growth: 7.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹78.37 | ₹70.53 - ₹86.21 | -13.9% | EPS Growth: 9.2%, Fair P/E: 7.4x |
| Growth Adjusted P/E | growth | ₹166.55 | ₹149.90 - ₹183.21 | +83.0% | Revenue Growth: 8.5%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹130.00 | ₹117.00 - ₹143.00 | +42.9% | ROE: 11.6%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹149.55 | ₹134.60 - ₹164.51 | +64.3% | EPS: ₹10.65, BVPS: ₹93.33 |
PAR Intrinsic Value vs Market Price — All Valuation Models
Par Drugs & Chemical fair value range ₹78–₹234 vs current market price ₹91.00 across 9 valuation models. Also explore Par Drugs & Chemical stock price data download to track price trends across different timeframes.
PAR Intrinsic Value Analysis — Undervalued or Overvalued?
Par Drugs & Chemical median intrinsic value ₹149.55, current price ₹91.00 — Trading Below Calculated Value by 64.3%, margin of safety 39.2%.
What is the intrinsic value of PAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Par Drugs & Chemical (PAR) is ₹149.55 (median value). With the current market price of ₹91.00, this represents a +64.3% variance from our estimated fair value.
The valuation range spans from ₹78.37 to ₹234.30, indicating ₹78.37 - ₹234.30.
Is PAR undervalued or overvalued?
Based on our multi-method analysis, Par Drugs & Chemical (PAR) appears to be trading below calculated value by approximately 64.3%.
PAR Financial Health — Key Ratios vs Industry Benchmarks
Par Drugs & Chemical financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 16.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.6% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.81x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PAR Cash Flow Quality — Operating & Free Cash Flow
Par Drugs & Chemical operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹20 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹10 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹12 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |